Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05962788 · ClinicalTrials.gov registry record · Phase 3
Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
A Phase 3 study, sponsored by Aurinia Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT05962788 is a Phase 3 study that was terminated before completion, run by Aurinia Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT05962788, a Phase 3 study, was terminated before completion, sponsored by Aurinia Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of voclosporin for up to an additional 12 months following completion of treatment in the AUR-VCS-2020-03 study (VOCAL) in adolescent and pediatric subjects with lupus nephritis.
Interventions
- DRUG voclosporin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2025-07-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05962788
The ClinicalTrials.gov registry entry for NCT05962788 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurinia Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which voclosporin is the first listed.
NCT05962788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05962788 about?
NCT05962788 is a clinical study titled "Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis". The purpose of this study is to assess the long-term safety and tolerability of voclosporin for up to an additional 12 months following completion of treatment in the AUR-VCS-2020-03 study (VOCAL) in adolescent and pediatric subjects with lupus nephritis.
What is the current status of trial NCT05962788?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2024-03-28. Estimated completion is 2025-07-04.
What interventions are being tested in trial NCT05962788?
The interventions under investigation include: voclosporin (DRUG).
Who is sponsoring clinical trial NCT05962788?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.